AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23417565 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 10
Study 23417565 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical items associated with mcAEs
Number of subjects: 10
Study 23417565 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for additional adverse event items
Number of subjects: 10
Study 23418134 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart phones
Number of subjects: 203
Study 23418134 — intervention group
Group type: COMPARATOR
Intervention: Non-smart phones
Number of subjects: 203
Study 23418272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment CMV DNA of <18,200 (4.3 log(10)) IU/mL
Number of subjects: 267
Study 23418272 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV load suppression <137 IU/mL (<2.1 log(10)) at days 7, 14, and 21
Number of subjects: 267
Study 23418288 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based gene expression score (GES)
Number of subjects: 537
Study 23418288 — intervention group
Group type: COMPARATOR
Intervention: Clinical factors and MPI
Number of subjects: 537
Study 23418734 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal function imager (RFI)
Number of subjects: 67
Study 23419735 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 4750
Study 23419735 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (Control)
Number of subjects: 4750
Study 23422236 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD Rating Scale (ADHD-RS)
Number of subjects: 892
Study 23422747 — intervention group
Group type: COMPARATOR
Intervention: IgH translocations in AA patients (40%)
Number of subjects: 115
Study 23422747 — intervention group
Group type: COMPARATOR
Intervention: Somatic copy number abnormalities in AA patients
Number of subjects: 115
Study 23422747 — intervention group
Group type: COMPARATOR
Intervention: Transcriptional profile associated with high-risk disease in AA patients
Number of subjects: 115
Study 23423135 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene nerve block
Number of subjects: 0
Study 23423135 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23424023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-balloon dilation
Number of subjects: 175
Study 23425164 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic device for sphincter augmentation
Number of subjects: 100
Study 23425215 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 53
Study 23425215 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 53
Study 23425215 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (baseline)
Number of subjects: 53
Study 23425514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous peritoneal lavage (PL) using the Velomedix Inc. automated PL system
Number of subjects: 16
Study 23425514 — intervention group
Group type: COMPARATOR
Intervention: Cooled saline intravenous infusions and cooled blankets (historical controls)
Number of subjects: 16
Study 23425514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous peritoneal lavage (PL)
Number of subjects: 16
Study 23425608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention twice weekly for eight months in addition to usual school health services
Number of subjects: 112
Study 23425608 — intervention group
Group type: COMPARATOR
Intervention: Usual school health services alone
Number of subjects: 112
Study 23425763 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary proteomics analysis
Number of subjects: 30
Study 23425763 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarkers for sepsis differentiation
Number of subjects: 30
Study 23426034 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of homocysteine (>9.85 μmol/L)
Number of subjects: 988
Study 23426034 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of homocysteine (≤6.74 μmol/L)
Number of subjects: 988
Study 23426034 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of cysteine (>309 μmol/L)
Number of subjects: 988
Study 23426034 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of cysteine (≤260 μmol/L)
Number of subjects: 988
Study 23426034 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine association with proximal colon tumors
Number of subjects: 988
Study 23426034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine association with rectal tumors
Number of subjects: 988
Study 23426034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine association with proximal tumors
Number of subjects: 988
Study 23426034 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine and cysteine associations with localized tumors
Number of subjects: 988
Study 23426034 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine and cysteine associations with metastases
Number of subjects: 988
Study 23426279 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR3419
Number of subjects: 7
Study 23426279 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR3419 + VXL (vincristine/dexamethasone/l-asparaginase)
Number of subjects: 7
Study 23426279 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR3419 (protracted therapy after VXL)
Number of subjects: 7
Study 23426337 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 490
Study 23426943 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Rapa cell infusion at day 14 post-HCT
Number of subjects: 40
Study 23426943 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Rapa cell infusion
Number of subjects: 40
Study 23427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Rice (CR)
Number of subjects: 42
Study 23427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-Zinc Rice (HZnR)
Number of subjects: 42
Study 23427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Rice plus Zinc Fortificant (CR+Zn)
Number of subjects: 42
Study 23428306 — intervention group
Group type: EXPERIMENTAL
Intervention: sGP130
Number of subjects: 563
Study 23428306 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 563
Study 23428306 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-6r
Number of subjects: 563
Study 23428306 — intervention group
Group type: COMPARATOR
Intervention: MetS
Number of subjects: 563
Study 23428875 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a 135-180 μg/week plus RBV 200-1200 mg/day for 48 weeks
Number of subjects: 32
Study 23428875 — intervention group
Group type: COMPARATOR
Intervention: Matched untreated historical controls (n=31)
Number of subjects: 32
Study 23428875 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a plus RBV
Number of subjects: 32
Study 23428875 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR
Number of subjects: 32
Study 23429230 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstruation phase
Number of subjects: 80
Study 23429230 — intervention group
Group type: EXPERIMENTAL
Intervention: Late follicular phase
Number of subjects: 80
Study 23429230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-luteal phase
Number of subjects: 80
Study 23429230 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of phases
Number of subjects: 80
Study 23429330 — intervention group
Group type: EXPERIMENTAL
Intervention: S80/V60 on days 1, 8, and 15
Number of subjects: 27
Study 23429330 — intervention group
Group type: EXPERIMENTAL
Intervention: S80/V80 on days 1, 8, and 15
Number of subjects: 27
Study 23429725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'-AmNic-rEPA (4-400 μg)
Number of subjects: 11
Study 23429998 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional class improvement from FC III to FC I/II (n=263)
Number of subjects: 982
Study 23429998 — intervention group
Group type: COMPARATOR
Intervention: Functional class unchanged (n=645)
Number of subjects: 982
Study 23429998 — intervention group
Group type: COMPARATOR
Intervention: Functional class worsened to FC IV (n=74)
Number of subjects: 982
Study 23429998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort with functional class improvement
Number of subjects: 982
Study 23429998 — intervention group
Group type: EXPERIMENTAL
Intervention: CTD cohort with functional class improvement
Number of subjects: 982
Study 23430175 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin hydrochloride for 3 days after each monthly IVT injection.
Number of subjects: 178
Study 23430175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 178
Study 23430598 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT), applied twice a week
Number of subjects: 690
Study 23430598 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 690
Study 23430599 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cardiac rehabilitation programme including four psychoeducative consultations and 12 weeks of individualised exercise training plus standard medical follow-up.
Number of subjects: 210
Study 23430599 — intervention group
Group type: COMPARATOR
Intervention: Standard medical follow-up (Control group).
Number of subjects: 210
Study 23432088 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-FICE plus pCLE
Number of subjects: 60
Study 23432088 — intervention group
Group type: COMPARATOR
Intervention: ME-FICE
Number of subjects: 60
Study 23432512 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 300
Study 23432512 — intervention group
Group type: COMPARATOR
Intervention: Decitabine
Number of subjects: 300
Study 23432512 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (in patients ≥ 65 years)
Number of subjects: 300
Study 23432512 — intervention group
Group type: COMPARATOR
Intervention: Decitabine (in patients ≥ 65 years)
Number of subjects: 300
Study 23433102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Number of subjects: 4069
Study 23433102 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine + artesunate (MQ + AS)
Number of subjects: 4069
Study 23433102 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 4069
Study 23433102 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 4069
Study 23433817 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched or fenestrated endografts
Number of subjects: 650
Study 23433846 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8330 (20 mg BID)
Number of subjects: 82
Study 23433846 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8330 (various doses)
Number of subjects: 82
Study 23433931 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE-CMR detected fibrosis
Number of subjects: 373
Study 23434121 — intervention group
Group type: COMPARATOR
Intervention: Moderately obese individuals
Number of subjects: 463
Study 23434121 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely obese individuals
Number of subjects: 463
Study 23434314 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 107
Study 23434314 — intervention group
Group type: EXPERIMENTAL
Intervention: reboxetine
Number of subjects: 107
Study 23434314 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 107
Study 23434626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Fidelis leads
Number of subjects: 976
Study 23434626 — intervention group
Group type: COMPARATOR
Intervention: Sprint Quattro leads
Number of subjects: 976
Study 23434626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint of mortality and heart failure hospitalisations
Number of subjects: 976
Study 23435023 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of body weight (healthy, underweight, or overweight)
Number of subjects: 689
Study 23435461 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT)
Number of subjects: 90
Study 23435697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence support approaches used in PrEP trials
Number of subjects: 0
Study 23435697 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-centered approaches
Number of subjects: 0
Study 23435697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored strategies beyond education
Number of subjects: 0
Study 23436052 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (RT) and vandetanib (a vascular endothelial growth factor receptor 2 inhibitor)
Number of subjects: 35
Study 23437092 — intervention group
Group type: EXPERIMENTAL
Intervention: ON SIROLIMUS AFTER 12 MONTHS
Number of subjects: 28
Study 23437092 — intervention group
Group type: COMPARATOR
Intervention: OFF SIROLIMUS AFTER 12 MONTHS
Number of subjects: 28
Study 23439103 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 23439103 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1800
Study 23439103 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score II
Number of subjects: 1800
Study 23439103 — intervention group
Group type: COMPARATOR
Intervention: Anatomical SYNTAX score
Number of subjects: 1800
Study 23439262 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r 150/100 mg once daily and ABT-072 400 mg once daily with weight-based ribavirin 1000-1200 mg/day dosed twice daily for 12 weeks
Number of subjects: 11
Study 23439262 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r and ABT-072 with ribavirin
Number of subjects: 11
Study 23439261 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment for 25.8 ± 3.7 months
Number of subjects: 50
Study 23439261 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 50
Study 23440228 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (n = 187; 32.9%)
Number of subjects: 568
Study 23440228 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment via antidepressant medication (n = 126; 22.2%)
Number of subjects: 568
Study 23440228 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (n = 39; 6.9%)
Number of subjects: 568
Study 23440355 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 0
Study 23440355 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study 23440998 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers prior to stem cell transplantation
Number of subjects: 109
Study 23440998 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger caregivers
Number of subjects: 109
Study 23440998 — intervention group
Group type: COMPARATOR
Intervention: Male and female caregivers
Number of subjects: 109
Study 23441892 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 31
Study 23442309 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided 20-gauge PTCNB
Number of subjects: 151
Study 23442518 — intervention group
Group type: EXPERIMENTAL
Intervention: Kochujang (KCJ) supplement (32 g/day)
Number of subjects: 60
Study 23442518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (32 g/day)
Number of subjects: 60
Study 23442588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV) administered in three doses with an interval of 4 to 10 weeks (28 to 70 days)
Number of subjects: 110
Study 23443063 — intervention group
Group type: EXPERIMENTAL
Intervention: SOPsystem
Number of subjects: 100
Study 23443063 — intervention group
Group type: COMPARATOR
Intervention: Food diaries (FDs) without SOPsystem
Number of subjects: 100
Study 23443507 — intervention group
Group type: EXPERIMENTAL
Intervention: UCN-01 65 mg/m(2) with perifosine 100 mg a day
Number of subjects: 13
Study 23443507 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifosine 150 mg every 6 h on day 1 followed by 100 mg once a day continuously in 28-day cycles
Number of subjects: 13
Study 23443507 — intervention group
Group type: EXPERIMENTAL
Intervention: UCN-01 at three dose levels (DL1=40 mg/m(2); DL2=65 mg/m(2); DL3=90 mg/m(2))
Number of subjects: 13
Study 23443507 — intervention group
Group type: EXPERIMENTAL
Intervention: UCN-01 and perifosine combination
Number of subjects: 13
Study 23443507 — intervention group
Group type: EXPERIMENTAL
Intervention: UCN-01 and perifosine
Number of subjects: 13
Study 23443729 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) in women
Number of subjects: 366
Study 23443729 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) in men
Number of subjects: 366
Study 23443729 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric Acid (UA)
Number of subjects: 366
Study 23443801 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg/m(2) administered daily on a seven-day-on, seven-day-off schedule for each 28-day cycle.
Number of subjects: 86
Study 23443801 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 86
Study 23443801 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum methylation assay
Number of subjects: 86
Study 23444221 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXC1-negative tumors
Number of subjects: 132
Study 23444221 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXC1 expression
Number of subjects: 132
Study 23444221 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXC1 copy number loss
Number of subjects: 132
Study 23444221 — intervention group
Group type: EXPERIMENTAL
Intervention: PBX1 copy number gain
Number of subjects: 132
Study 23444221 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXC1 protein expression
Number of subjects: 132
Study 23445216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 32
Study 23445216 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 23445875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Number of subjects: 148
Study 23445875 — intervention group
Group type: EXPERIMENTAL
Intervention: High hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Number of subjects: 148
Study 23445876 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim to Eltrombopag
Number of subjects: 46
Study 23445876 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag to Romiplostim
Number of subjects: 46
Study 23445876 — intervention group
Group type: COMPARATOR
Intervention: Romiplostim
Number of subjects: 46
Study 23445876 — intervention group
Group type: COMPARATOR
Intervention: Eltrombopag
Number of subjects: 46
Study 23445876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 46
Study 23446180 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention to improve health literacy and HIV medication adherence
Number of subjects: 0
Study 23446180 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention
Number of subjects: 0
Study 23446828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 734
Study 23446828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 734
Study 23447001 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd)
Number of subjects: 40
Study 23447571 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 21
Study 23447571 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite pacing using distal and proximal LV electrodes
Number of subjects: 21
Study 23447571 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite pacing configurations
Number of subjects: 21
Study 23447571 — intervention group
Group type: EXPERIMENTAL
Intervention: All tested configurations of multisite pacing
Number of subjects: 21
Study 23447571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing from most distal and proximal electrodes
Number of subjects: 21
Study 23448187 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP sensor lead extraction using manual traction with a locking stylet and/or excimer laser sheath
Number of subjects: 82
Study 23448187 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual traction alone
Number of subjects: 82
Study 23448187 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser sheath (used in selected cases)
Number of subjects: 82
Study 23448727 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate (0, 24, 48 hours)
Number of subjects: 215
Study 23449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible diffusion hyperintensities (RDHs) observed in patients after stroke.
Number of subjects: 153
Study 23449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete normalization of MR images.
Number of subjects: 153
Study 23449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of RDHs related to multiple infarct pattern.
Number of subjects: 153
Study 23449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of RDHs related to symptomatic carotid stenosis.
Number of subjects: 153
Study 23449267 — intervention group
Group type: EXPERIMENTAL
Intervention: New additional lesions on follow-up DWI in patients with RDHs.
Number of subjects: 153
Study 23449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional improvement on the National Institutes of Health Stroke Scale score.
Number of subjects: 153
Study 23449428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1809
Study 23451835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg daily for 4 weeks (NERD)
Number of subjects: 3313
Study 23451835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg daily for 8 weeks (EO)
Number of subjects: 3313
Study 23451835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 8 weeks (EO)
Number of subjects: 3313
Study 23451835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NERD)
Number of subjects: 3313
Study 23451840 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures for patients with increased familial risk of CRC
Number of subjects: 358
Study 23451840 — intervention group
Group type: COMPARATOR
Intervention: Preventive measures for low-risk patients
Number of subjects: 358